Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Results from the ongoing BeyoND study

被引：0
|
作者：
Poewe, W. [1 ]
Stocchi, F. [2 ]
Sopromadze, S. [3 ]
Adar, L. [3 ]
Sasson, N. [3 ]
Yardeni, T. [3 ]
Giladi, N. [4 ]
机构：
[1] Med Univ Innsbruck, Innsbruck, Austria
[2] Univ & Inst Res & Med Care IRCCS San Raffaele, Rome, Italy
[3] NeuroDerm, Rehovot, Israel
[4] Tel Aviv Univ, Neurol Inst, Tel Aviv Med Ctr, Sackler Sch Med,Sagol Sch Neurosci, Tel Aviv, Israel
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-017
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [1] Long-Term Safety of Continuous Levodopa/Carbidopa Infusion with ND0612: Results from the Ongoing BeyoND Study
    Isaacson, S.
    Stocchi, F.
    Adar, L.
    Case, R.
    Sasson, N.
    Salin, L.
    Yardeni, T.
    Poewe, W.
    MOVEMENT DISORDERS, 2022, 37 : S10 - S10
  • [2] LONG-TERM SAFETY OF CONTINUOUS LEVODOPA/CARBIDOPA INFUSION WITH ND0612: RESULTS FROM THE ONGOING BEYOND STUDY
    Poewe, W.
    Stocchi, F.
    Sopromadze, S.
    Adar, L.
    Sasson, N.
    Yardeni, T.
    Giladi, N.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 46 - 46
  • [3] Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Data from patients who continued past one year in the BeyoND study
    Isaacson, S.
    Giladi, N.
    Stocchi, F.
    Salin, L.
    Vostokova, N.
    Poewe, W.
    MOVEMENT DISORDERS, 2022, 37 : S334 - S334
  • [4] Quality of life with continuous subcutaneous levodopa/carbidopa infusion: Exploratory findings from the ND0612 BeyoND study
    Espay, Alberto
    Yardeni, Tami
    Adar, Liat
    Case, Ryan
    Poewe, Werner
    Isaacson, Stuart
    MOVEMENT DISORDERS, 2023, 38 : S16 - S16
  • [5] Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study
    Isaacson, S.
    Poewe, W.
    Simuni, T.
    Rosenfeld, O.
    Case, R.
    Yardeni, T.
    Olanow, W.
    MOVEMENT DISORDERS, 2020, 35 : S401 - S401
  • [6] Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study
    Ellenbogen, Aaron L.
    Poewe, Werner
    Espay, Alberto J.
    Simuni, Tanya
    Gurevich, Tanya
    Yardeni, Tami
    Lopes, Nelson
    Sasson, Nissim
    Case, Ryan
    Stocchi, Fabrizio
    BeyoND Study Grp
    PARKINSONISM & RELATED DISORDERS, 2025, 132
  • [7] Pharmacokinetic-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
    Birnberg, T.
    Adar, L.
    Poewe, W.
    Bjornsson, M.
    Karlsson, M.
    MOVEMENT DISORDERS, 2021, 36 : S162 - S162
  • [8] Quality of life and patient reported outcomes with subcutaneous levodopa/carbidopa infusion: findings from the ND0612 BeyoND study
    Poewe, W.
    Stocchi, F.
    Adar, L.
    Yardeni, T.
    Espay, A.
    MOVEMENT DISORDERS, 2022, 37 : S347 - S347
  • [9] The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
    LeWitt, Peter A.
    Stocchi, Fabrizio
    Arkadir, David
    Caraco, Yoseph
    Adar, Liat
    Perlstein, Itay
    Case, Ryan
    Giladi, Nir
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [10] Continuous Subcutaneous Levodopa/Carbidopa Infusion with ND0612 For Parkinson's Disease: Three-year Data from the Openlabel BeyoND Study
    Poewe, W.
    Ellenbogen, A.
    Stocchi, F.
    Adar, L.
    Salin, L.
    Case, R.
    Yardeni, T.
    Giladi, N.
    MOVEMENT DISORDERS, 2023, 38 : S46 - S46
12345